American Portfolios Advisors’s Pacific Biosciences PACB Stock Holding History

American Portfolios Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$171K	Sell	29,541 -445	-1%	-$2.55K	0.01%	1078
2022 Q2	$133K	Sell	29,986 -483	-2%	-$2.94K	0.01%	1259
2022 Q1	$277K	Buy	30,469 +2,313	+8%	+$26.6K	0.01%	1012
2021 Q4	$576K	Buy	28,156 +14,724	+110%	+$355K	0.02%	682
2021 Q3	$343K	Sell	13,432 -3,445	-20%	-$102K	0.01%	884
2021 Q2	$590K	Buy	16,877 +15,602	+1,224%	+$454K	0.02%	643
2021 Q1	$42.5K	Buy	1,275 +350	+38%	+$12.3K	﹤0.01%	1674
2020 Q4	$24K	Buy	+925	New	+$15.7K	﹤0.01%	1733
2019 Q2	–	Sell	-500	Closed	-$3.62K	–	2776
2019 Q1	$3.62K	Buy	+500	New	+$3.62K	﹤0.01%	2195

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Portfolios Advisors's PACB Position: Q3 2022 in Review

American Portfolios Advisors reduced its Pacific Biosciences (PACB) stake by 1.5% in Q3 2022, selling an estimated $2.55K and leaving 29,541 shares worth $171K. The position accounts for 0.01% of the portfolio, ranked #1078.

American Portfolios Advisors first reported a position in PACB in Q1 2019 and has held it in 9 quarters since. The position peaked at $590K in Q2 2021. 227 funds tracked by Wall St. Rank hold PACB as of Q3 2022.

American Portfolios Advisors held 29,541 shares of Pacific Biosciences worth $171K as of Q3 2022.
American Portfolios Advisors sold 445 Pacific Biosciences shares in Q3 2022, an estimated $2.55K.
Pacific Biosciences made up 0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #1078 holding.
American Portfolios Advisors first reported a position in Pacific Biosciences in Q1 2019 and has held it in 9 quarters since.
American Portfolios Advisors's Pacific Biosciences position peaked at $590K in Q2 2021.
227 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.